JP2021523120A5 - - Google Patents
Info
- Publication number
- JP2021523120A5 JP2021523120A5 JP2020561740A JP2020561740A JP2021523120A5 JP 2021523120 A5 JP2021523120 A5 JP 2021523120A5 JP 2020561740 A JP2020561740 A JP 2020561740A JP 2020561740 A JP2020561740 A JP 2020561740A JP 2021523120 A5 JP2021523120 A5 JP 2021523120A5
- Authority
- JP
- Japan
- Prior art keywords
- peaks
- acid
- compound
- salt according
- furthermore
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862667226P | 2018-05-04 | 2018-05-04 | |
| US62/667,226 | 2018-05-04 | ||
| PCT/US2019/030717 WO2019213606A2 (en) | 2018-05-04 | 2019-05-03 | Solid forms of cerdulatinib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523120A JP2021523120A (ja) | 2021-09-02 |
| JP2021523120A5 true JP2021523120A5 (enExample) | 2022-05-12 |
| JP7324778B2 JP7324778B2 (ja) | 2023-08-10 |
Family
ID=66641481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561740A Active JP7324778B2 (ja) | 2018-05-04 | 2019-05-03 | セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US10865198B2 (enExample) |
| EP (1) | EP3788035B1 (enExample) |
| JP (1) | JP7324778B2 (enExample) |
| TW (1) | TW202014412A (enExample) |
| WO (1) | WO2019213606A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10736895B2 (en) | 2015-12-04 | 2020-08-11 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating hematological cancers |
| WO2019213606A2 (en) * | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
| TWI805751B (zh) * | 2018-05-04 | 2023-06-21 | 美商普托拉製藥有限公司 | 賽度替尼(cerdulatinib)之合成 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60255756A (ja) | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| WO1995032963A1 (en) | 1994-06-01 | 1995-12-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienylazole compound and thienotriazolodiazepine compound |
| WO2003037352A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-phenyl-5-n-heterocyclyl-pyrazoles as cyclooxygenase inhibitors for the treatment of inflammation associated disorders |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| EP1518855B1 (en) | 2002-06-28 | 2011-10-26 | Astellas Pharma Inc. | Diaminopyrimidinecarboxa mide derivative |
| WO2008009458A1 (en) | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| DK2526933T3 (en) | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| HRP20161310T1 (hr) | 2008-04-16 | 2016-12-02 | Portola Pharmaceuticals, Inc. | 2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza |
| US8367689B2 (en) | 2009-05-06 | 2013-02-05 | Portola Pharmaceuticals, Inc. | Inhibitors of JAK |
| WO2010138588A2 (en) | 2009-05-26 | 2010-12-02 | Abbott Laboratories | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US20120157500A1 (en) | 2009-08-24 | 2012-06-21 | Weikang Tao | Jak inhibition blocks rna interference associated toxicities |
| EP2507227B1 (en) | 2009-12-01 | 2014-10-08 | Rigel Pharmaceuticals, Inc. | Tetrazolones as protein kinase c inhibitors and uses thereof |
| US9357229B2 (en) | 2010-07-28 | 2016-05-31 | Qualcomm Incorporated | Coding motion vectors in video coding |
| EP2621489A1 (en) | 2010-09-30 | 2013-08-07 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| PT2643322T (pt) | 2010-11-23 | 2017-11-13 | Abbvie Inc | Sais e formas cristalinas de um agente indutor de apoptose |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
| TW201427664A (zh) | 2012-11-02 | 2014-07-16 | Pharmacyclics Inc | Ｔｅｃ家族激酶抑制劑佐劑療法 |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| JP7258462B2 (ja) | 2015-05-29 | 2023-04-17 | ポートラ ファーマシューティカルズ， エルエルシー | Ｂ細胞悪性腫瘍の治療のためのセルデュラチニブ |
| JP6833816B2 (ja) | 2015-08-12 | 2021-02-24 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 骨髄腫を治療するためのセルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ） |
| US10736895B2 (en) | 2015-12-04 | 2020-08-11 | Portola Pharmaceuticals, Inc. | Cerdulatinib for treating hematological cancers |
| CA3098012A1 (en) | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Methods for treating lymphoma |
| TWI805751B (zh) | 2018-05-04 | 2023-06-21 | 美商普托拉製藥有限公司 | 賽度替尼(cerdulatinib)之合成 |
| WO2019213606A2 (en) * | 2018-05-04 | 2019-11-07 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
-
2019
- 2019-05-03 WO PCT/US2019/030717 patent/WO2019213606A2/en not_active Ceased
- 2019-05-03 EP EP19726240.5A patent/EP3788035B1/en active Active
- 2019-05-03 JP JP2020561740A patent/JP7324778B2/ja active Active
- 2019-05-03 US US16/402,684 patent/US10865198B2/en active Active
- 2019-05-03 TW TW108115465A patent/TW202014412A/zh unknown
-
2020
- 2020-11-16 US US17/098,852 patent/US11713309B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523120A5 (enExample) | ||
| JP7036939B2 (ja) | 癌細胞の成長抑制効果を示す新規なピリミジン誘導体及びそれを含む薬剤学的組成物 | |
| US8513256B2 (en) | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| JP7126514B2 (ja) | アミノピリジン誘導体化合物の塩、その結晶形態、及びその調製プロセス | |
| CN103930399B (zh) | 包含亚氨基亚磺酰基的二取代的5-氟嘧啶衍生物 | |
| TW438781B (en) | Substituted 1,2,3,4-tetrahydronaphthalene derivatives | |
| US20080293711A1 (en) | Chemokine receptor modulators | |
| TW201000460A (en) | Amide compound | |
| JP4429724B2 (ja) | ［１，２，４］−トリアゾール二環式アデノシンＡ２ａレセプタアンタゴニスト | |
| TWI425945B (zh) | 四氫異喹啉－１－酮衍生物或其鹽 | |
| TW200307539A (en) | Cycloalkyl inhibitors of potassium channel function | |
| WO2008109154A1 (en) | Chemokine receptor modulators | |
| TW200932727A (en) | New acetyl coenzyme a carboxylase (ACC) inhibitors and uses in treatments of obesity and diabetes mellitus | |
| CZ20033508A3 (en) | 5-ht receptor ligands and uses thereof | |
| WO2004110986A1 (ja) | ベンズアミド誘導体又はその塩 | |
| TW201105325A (en) | 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamides | |
| CN101258131B (zh) | 作为5-HT2c受体激动剂的6-芳烷基氨基-2,3,4,5-四氢-1H-苯并[d]氮杂䓬 | |
| CN101506215A (zh) | 腺苷A2a受体拮抗剂 | |
| JPWO2008105442A1 (ja) | スルホンアミド誘導体 | |
| TW201010978A (en) | Substituted isoquinolines and isoquinolinones | |
| TW200815368A (en) | 2-anilino-4-aminoalkyleneaminopyrimidines | |
| CN102741226B (zh) | 4-取代的-2-苯氧基-苯胺δ阿片类受体调节剂 | |
| EP2906554A1 (en) | Solid forms of nilotinib hydrochloride | |
| JP2023078389A (ja) | 重水素化デファクチニブ化合物及びその使用 | |
| DE60201819T2 (de) | Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren |